Arcturus Therapeutics Holdings Inc. (ARCT), a commercial mRNA medicines company with a pipeline of multiple therapeutic candidates in advanced clinical trial development, is scheduled to report interim data from its cystic fibrosis study of ARCT-032 this month.
ARCT-032 is an inhaled investigational mRNA therapeutic designed to express a normal functional cystic fibrosis transmembrane conductance regulator (CFTR) gene in the lungs of individuals with cystic fibrosis. Mutations in the CFTR gene cause cystic fibrosis. There are over 2,000 mutations of the Cystic Fibrosis Transmembrane (CFTR) gene.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com